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Background: Allergoids are chemically modified allergen extracts administered to reduce allergenicity and to maintain
immunogenicity. Oralair® (the 5-grass tablet) is a sublingual native grass allergen tablet for pre- and co-seasonal
treatment. Based on a literature review, meta-analysis, and cost-effectiveness analysis the relative effects and costs of
the 5-grass tablet versus a mix of subcutaneous allergoid compounds for grass pollen allergic rhinoconjunctivitis were
assessed.
Methods: A Markov model with a time horizon of nine years was used to assess the costs and effects of three-year
immunotherapy treatment. Relative efficacy expressed as standardized mean differences was estimated using an
indirect comparison on symptom scores extracted from available clinical trials. The Rhinitis Symptom Utility Index (RSUI)
was applied as a proxy to estimate utility values for symptom scores. Drug acquisition and other medical costs were
derived from published sources as well as estimates for resource use, immunotherapy persistence, and occurrence of
asthma. The analysis was executed from the German payer’s perspective, which includes payments of the Statutory
Health Insurance (SHI) and additional payments by insurants. Comprehensive deterministic and probabilistic sensitivity
analyses and different scenarios were performed to test the uncertainty concerning the incremental model outcomes.
Results: The applied model predicted a cost-utility ratio of the 5-grass tablet versus a market mix of injectable allergoid
products of € 12,593 per QALY in the base case analysis. Predicted incremental costs and QALYs were € 458 (95%
confidence interval, CI: € 220; € 739) and 0.036 (95% CI: 0.002; 0.078), respectively. Compared to the allergoid mix the
probability of the 5-grass tablet being the most cost-effective treatment option was predicted to be 76% at a
willingness-to-pay threshold of € 20,000. The results were most sensitive to changes in efficacy estimates, duration of
the pollen season, and immunotherapy persistence rates.
Conclusions: This analysis suggests the sublingual native 5-grass tablet to be cost-effective relative to a mix of
subcutaneous allergoid compounds. The robustness of these statements has been confirmed in extensive sensitivity
and scenario analyses.* Correspondence: bverheggen@pharmerit.com
1Pharmerit International, Marten Meesweg, 107 3068AV Rotterdam, The
Netherlands
Full list of author information is available at the end of the article
© 2015 Verheggen et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Verheggen et al. Clinical and Translational Allergy  (2015) 5:1 Page 2 of 10Background
According to the World Health Organization (WHO), al-
lergic respiratory diseases have been recognized as the
fourth most important chronic disease in the world and
represent a major public health problem with significant
quality of life (QoL) impairment [1]. With approximately
one in four people presenting with clinical symptoms of
allergies, the number of affected patients significantly in-
creased in Western countries. About 90 million Europeans
and 65 million Americans are affected by allergic respira-
tory diseases. Furthermore, 10 to 40% of patients with al-
lergic rhinitis (AR) also have allergic asthma [2-4]. In
Germany, 25% of the adult population and 21% of children
suffer from AR. If untreated, AR leads to allergic asthma
in 43% of the patients [5]. A lifetime prevalence of 14.8%
for AR was reported [6]. Growing incidence and preva-
lence of allergic disorders are major reasons for the in-
creasing need for allergen immunotherapy (AIT).
AR is an inflammation of the nasal passage that is char-
acterized by a combination of the following symptoms:
sneezing, nasal itching and/or congestion, rhinorrhoea
and watery and itchy eyes [7,8]. It is caused by allergens,
including proteins and glycoproteins of house dust mite
fecal particles, molds, and grass or tree pollens [9].
Treatment of AR mainly consists of symptom control
achieved by allergen avoidance or use of pharmacotherapy
such as antihistamines. Since symptomatic medications
have no long-lasting effect following discontinuation and
some patients remain uncontrolled, causal treatments like
AIT may be required in persistent disease and should
begin as early as possible [2,10-12]. AIT interferes with
basic mechanisms of allergy and alters the natural course
of the disease offering long-lasting, disease-modifying and
preventive effects. It is mostly used in two main types of
formulations: Sublingual immunotherapy (SLIT) and sub-
cutaneous immunotherapy (SCIT). SLIT uses an allergenic
solution or tablet, applied under the tongue, which over
the course of treatment reduces sensitivity to allergens.
SLIT has a proven good safety profile, is convenient for
patients and both adults and children can be treated at
home [13]. In contrast, SCIT is administered by the doctor
in form of injections.
Oralair® (the 5-grass tablet) is a SLIT tablet for treatment
of seasonal, grass pollen induced AR. The active substance
of the 5-grass tablet comprises freeze-dried extracts from
five grasses: perennial rye (Lolium perenne), meadow (Poa
pratensis), timothy (Phleum pratense), cocksfoot (Dactylis
glomerata), and sweet vernal grass (Anthoxanthum odora-
tum) [14]. These substances correlate with the epidemio-
logical data of patient exposure in Europe.
To provide healthcare resources within the restrictions
of the healthcare system, physicians and decision-makers
carefully assess the clinical benefits and economic conse-
quences of different AIT treatments. Accordingly, a studywas conducted in 2010 to assess the cost-effectiveness of
the 5-grass tablet compared to Grazax® (SLIT mono-grass
tablet), Alutard® (SCIT with native extracts) and symptom-
atic treatment for grass pollen induced AR in Germany
[15]. The outcomes were based on a systematic review of
the literature, a meta-analysis and the application of these
clinical outcomes in a cost-effectiveness framework. Aller-
goids, chemically modified SCIT treatments, are a relevant
competitor group in the German market. Therefore, a
comparison of the 5-grass tablet versus allergoid prod-
ucts was performed: The meta-analysis was updated
(see Additional file 1) and the existing cost-effectiveness
model was extended to assess the relative effects and costs
of the sublingual 5-grass tablet versus a relevant variety of




A Markov-model with a nine-year time horizon was ap-
plied to predict the distribution of patients over a num-
ber of health states over a sequence of discrete one-year
time periods after receiving therapy, and subsequently to
assess the associated costs and effects (Figure 1). A simi-
lar model was constructed in the cost-effectiveness ana-
lysis by Westerhout et al. [15].
Patients who entered the analysis either received AIT
with the 5-grass tablet or an averaged hypothetical aller-
goid mix, both with optional symptomatic medication in
addition, or underwent symptomatic treatment alone. The
length of the pollen season was estimated at three months
per year [16]. After discontinuation, solely symptomatic
treatment was continued in the model. To capture both
symptom control and immunologic impairment several
health states were included in the model. In each state, pa-
tients could develop chronic asthma accompanied by an
increased risk of dying. Every treatment arm generated
corresponding symptom scores, symptom-free days, util-
ities and costs (see below).
Model inputs
Patient population
Patients included in the model (mean age 29 years) suffered
from grass pollen AR and/or conjunctivitis with a positive
grass allergen-specific skin prick test and/or elevated serum
grass allergen-specific IgE. Baseline characteristics of the
modelled cohort reflect the average patient characteristics
in the treatment arms of the included clinical trials. At entry
time, none of the patients suffered from co-existing chronic
asthma. Only intermittent use of ß-agonists was allowed.
Comparators
Within the available range of allergoid products, the most
widely used products in Germany with citable references
Figure 1 Structure of the applied Markov model with a cycle length of one year. Patients enter the model receiving either AIT (5-grass
tablet/allergoids) or symptomatic treatment alone. AIT, allergen specific immunotherapy.
Table 1 Randomized controlled trials (RCTs) for the 5-grass
tablet and the allergoid mix
RCT




Allergoid mix Pfaar 2012 (Depiquick) [22]
Corrigan 2009 (Allergovit) [23]
Drachenberg 2001 (Pollinex) [24]
Du Buske 2011 (Pollinex) [25]
Brewczynski 1999 (Purethal) [26]
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identified. The allergoid SCITs, namely Allergovit®, Depi-
quick®, Pollinex® Quattro and Purethal® (all for grasses),
met the search criteria. The data was then grouped and av-
eraged as one single comparator (see also Additional file 1).
As the clinical evidence for most of the individual com-
pounds was too limited presenting only low patient num-
bers, grouping was indicated to obtain resilient efficacy
data. Finally, symptomatic treatment (according to the tri-
als’ standards) was included as a comparator.
Symptom scores and transition probabilities
In order to obtain symptom scores from all treatment
arms used in the cost-effectiveness study, a literature re-
view and network meta-analysis (type: indirect treatment
comparison) were performed.
Clinical trial data on allergoid compounds published
before March 2012 was retrieved from a meta-analysis
performed by Di Bona et al. [17] (Table 1). In addition,
the PubMed-database was searched to identify random-
ized control trials (RCTs) for all the included com-
pounds published between March 2012 and May 2013
(Table 1). The literature review and indirect comparison
is detailed in the Additional file 1. AIT is typically ad-
ministered during three consecutive seasons, and it was
assumed that drug effects during these three seasons
could be viewed as independent. Therefore, the symp-
tom scores reported in clinical trials during the on-
treatment years were pooled in the indirect comparison,
resulting in one single value per treatment. Rhinocon-
junctivits Total Symptom Scores (RTSS) values were: 5-
grass tablet 3.26, allergoid mix 3.64, and symptomatic
treatment 4.47. Rates for discontinuation, developing
asthma and mortality as implemented in the model are
shown in Table 2. It was further assumed that these
symptom score values remain constant during the post-
treatment period in the model.Utility values
For clinical trials and cost-effectiveness studies, the Rhinitis
Symptom Utility Index (RSUI) has been developed. RSUI
represents a preference-based utility index for rhinitis
symptoms using standard gamble and visual analogue scale
(VAS) [33]. Using this scoring index, symptom severity can
be converted to utility. Patients’ QoL values were further
determined by patient’s age and co-existing asthma during
the pollen season [34,35].
Costs
The analysis was conducted from the German payer per-
spective, including payments of the SHI and additional
payments by insurants. All AIT agents were used for a
maximum time period of three years. Costs for the 5-
grass tablet administered once daily were based on usage
of seven months per year (pre-seasonal and co-seasonal)
in the base case analysis [14]. For the allergoid mix (see
above), a weighted average cost was calculated based on
German market shares (December 2011). For all aller-
goid compounds, one package was sufficient to treat a
patient before and/or during the season [36-38].
Table 2 Transition probabilities applied in the model
Parameter Probability Reference
Discontinuation SLIT (5-grass tablet) Year 1 0.29 [27]
Year 2 0.28 [27]
Discontinuation SCIT (allergoid mix) Year 1 0.41 [27]
Year 2 0.34 [27]
Developing asthma with symptomatic
treatment
0.0046 [28]
Relative risk developing asthma
(AIT vs. symptomatic treatment)
0.505 [29,30]
All population mortality* 0.00046 [31]
Asthma mortality* 0.00069 [32]
*Probabilities represent mortality at start of the analysis (29 years).
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payments. Additionally, costs for symptomatic medication
were calculated by multiplying the costs of loratadine and
budesonide by the number of actuations. The number of
tablets and puffs used during the season for the AIT and
symptomatic treatment arm presented in Bachert et al.
[39] were adjusted for an average pollen season’s length of
three months (Table 3).
Apart from pharmaceutical costs, the model included
costs for specialist visits, treatment administration, diag-
nostics and asthma. In Germany, costs for health care are
paid in four different settings: Public sector (90%), which is
separated in lump sums (80%) [40], ambulatory hospital
setting (15%) [41], and visits to a doctor who is remuner-
ated by the schedule of port fees and charges for doctors
(Gebührenordnung für Ärzte, GOÄ) instead of the generalTable 3 Treatment costs
Model parameter Value
Costs of immunotherapy treatment over a 3-year treatment
period
5-grass tablet € 2,100.10
Allergoid mix € 1,449.60
Seasonal costs and symptomatic medication per season
Loratadine AIT € 5.14
Symptomatic treatment € 7.54
Budesonide AIT € 2.19
Symptomatic treatment € 3.83
Weighted average costs of resource use
Specialist visit 10 minutes € 13.29
Additional costs visits > 10 min € 3.69
AIT injection € 5.11
Diagnostic tests € 20.61
Costs of asthma indexed for 2013
2010 € 175.00
2013 € 186.30assessment standard (Einheitlicher Bewertungsmaßstab,
EBM) (5%) [39]. The last setting is private health care in-
surance (10%) [42]. Table 3 presents the average resource
cost of all four remuneration options.
The number of specialist visits associated with the use
of the allergoid mix was estimated based on a weighted
average of the number of injections each year taken from
the Summary of Product Characteristics (SmPC). 5-grass
tablet patients were assumed to see their doctor every
three months during treatment for optimal adherence
[43]. All patients on immunotherapy were estimated to
have one visit for a diagnostic test in the first year. After
three years of AIT treatment all patients were expected
to have 1.9 visits per year [44]. Finally, three references
were used to derive the cost for asthma [45-47] and are
presented in Table 3.
Model outcomes
Model outcomes were calculated and presented as total
and incremental (un)discounted QALYs and costs. Then, a
cost per Quality Adjusted Life year (QALY) was derived
for the 5-grasss tablet and the allergoid mix. In accordance
with the guideline for pharmacoeconomic research in
Germany, discounting was applied at 3% per year for both
costs and effects [48].
Sensitivity analyses
Deterministic and probabilistic sensitivity analyses (PSA)
were performed as well as a number of scenarios to as-
sess the influence of uncertainty of input parameters. To
identify the main drivers of the model outcomes, all un-
certain parameters were placed separately at their outer
limits of their 95% confidence intervals within the deter-
ministic univariate sensitivity analyses.
To constitute the uncertainty around the predicted incre-
mental costs and effects, 1.000 simulations were performed
in the PSA by simultaneously changing the parameters by
random draws from their estimated distributions. For
transition probabilities and utility values, beta distribution
was applied. Normal distributions were used in case of risk
estimates, and treatment efficacy of the 5-grass tablet, and
allergoid mix (standardized mean difference values, SMDs).
Gamma distributions were applied for healthcare costs and
the duration of the pollen season. If the publication did not
provide information on variance, the standard error was
supposed to vary 20% around the mean value.
A scatterplot and an acceptability curve were designed
estimating the 95% confidence intervals around incre-
mental model outcomes and the probability of the 5-
grass tablet being cost-effective versus its comparators at
a given willingness-to-pay (WTP) threshold per obtained
QALY. Since the effects of assumptions and choices may
not be completely captured by the sensitivity analyses, a
number of scenario analyses were carried out.
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on the distribution of patients on the various remuner-
ation pathways. Due to variations in this respect, costs
for specialist visits, treatment administration, and diag-
nostics were calculated based on lump sum payments
(scenario 1) and the ambulatory setting (scenario 2).
In another scenario, costs were obtained from the soci-
etal perspective, incorporating indirect costs. Labour hours
missed [39] over one season due to specialist visits e.g.
were multiplied by the cost of one labour hour (€ 30.70)
[42,49]. In a fourth scenario, the utility data were based on
a different literature source. Utility values measured with
the EQ-5D associated with another mono-grass tablet
(Grazax®) (0.976) and symptomatic treatment (0.947) were
also available from a cost-effectiveness study [39]. As only
data for the mono-grass tablet existed, AIT agents consid-
ered in the current analysis (5-grass tablet/allergoid mix)
were assumed to all be associated with the same utility
value of 0.947.
Since the length of the pollen season varies in different
geographical areas, in scenario 5 a shorter duration of




The results after nine years indicate higher total and in-
cremental effects (QALYs) for the 5-grass tablet, for both
discounted and undiscounted values (Table 4). This is
based on the better efficacy of the 5-grass tablet in terms
of RTSS compared with the allergoid mix. Additionally,
AIT with the 5-grass tablet results in a lower total num-
ber of incidental asthma patients compared to symptom-
atic treatment.
Costs
AIT treatment with the allergoid mix show a substantial
use of health care services, as injections need to be admin-
istered by the specialist. Analyzing the absolute and rela-
tive distribution of the total costs over separate cost
components, AIT treatment costs were found to be the
main cost drivers (61–78% of the total amount), followed
by cost for dermatologist visits (Table 4). Discounted and
undiscounted values of total and incremental costs are dis-
played in Table 4.
Incremental cost effectiveness ratio (ICER)
Table 4 presents estimates of incremental costs and effects
after nine years of treatment and follow-up, both dis-
counted and undiscounted. These incremental values re-
sult in a cost-effectiveness ratio of the 5-grass tablet
relative to symptomatic treatment of € 17,007 per QALY.
For the 5-grass tablet vs. allergoid mix the ICER is
€ 12,593 per QALY.Sensitivity analyses
For the comparisons of the 5-grass tablet versus allergoid
mix, extensive deterministic univariate sensitivity analyses
and one probabilistic multivariate sensitivity analysis have
been conducted, as well as a number of scenarios.
Deterministic univariate sensitivity analyses
Incremental QALYs resulting from the calculations are
mainly sensitive to changes in efficacy estimates, because
these are directly linked to utilities from the RSUI
(Figure 2a). The length of the pollen season shows an in-
fluence on the incremental QALYs. The longer the season,
the more QALYs gained for the 5-grass tablet versus its
comparators due to the higher RSUI for the 5-grass tablet.
Furthermore, changes in discontinuation rates have a
slight effect on the results. When comparing the 5-grass
tablet vs. the allergoid mix, the incremental costs are most
sensitive to the length of the pollen season, as the cost for
5-grass tablet depends on a season’s duration (Figure 2b).
Furthermore, incremental costs are most sensitive to
probabilities of immunotherapy discontinuation. In gen-
eral cost outcomes are only mildly influenced by param-
eter uncertainty, as immunotherapy treatment is the main
cost driver behind the results on incremental costs.
Probabilistic multivariate sensitivity analysis
The joint uncertainty around the incremental costs and
QALYs are displayed in Figure 3. The percentage of simula-
tions which predicts positive effects and higher costs is esti-
mated at 98% when the 5-grass tablet is compared to the
allergoid mix. The 95% confidence intervals for the incre-
mental QALYs are 0.002 to 0.079 for 5-grass tablet vs. aller-
goid mix. The 95% confidence intervals for costs are € 192
to € 718. Figure 4 present the acceptability curves of the 5-
grass tablet and the allergoid mix. At a willingness-to-pay
threshold of € 20,000, the probability of the 5-grass tablet
being the most cost-effective treatment is predicted at 76%.
Scenario analyses
In the first two scenario analyses, healthcare costs are cal-
culated by lump sums or 1 fold GOÄ (Gebührenordnung
für Ärzte, remuneration catalogue for physicians) prices. In
contrast to the first scenario, the second one did remuner-
ate for extra services performed by the physician. As a re-
sult, incremental costs of the 5-grass tablet increased (lump
sums) and decreased (1-fold GOÄ) versus SCIT allergoids,
since injections correspond to extra visits (Table 5).
By including productivity losses as performed in scenario
3, incremental costs of the 5-grass tablet versus the aller-
goid mix and symptomatic treatment decreased, because
treatment with AIT is associated with fewer hours lost from
work [50]. The study of Peterson et al. revealed that sick
days were reduced from 3.7 to 1.2 days by the treatment
with AIT [50]. Utility data from Bachert et al. [39] were
Figure 2 Results of the deterministic univariate sensitivity analyses. a) Tornado graph representing outer limits of incremental QALYs for the
5-grass tablet vs. allergoid mix and b) Tornado graph representing outer limits of incremental costs for the 5-grass tablet vs. allergoid mix.
Table 4 Base case results
Overview of base case results comparing SLIT allergen and SCIT allergoid immunotherapy
Discounted and undiscounted total QALYs per treatment after a time horizon of 9 years
Discounted Undiscounted
5-grass tablet 7.316 8.207
Allergoid mix 7.280 8.166
Symptomatic tx 7.235 8.116
Absolute and relative distribution of total undiscounted costs over individual cost components after 9 years
5-grass tablet Allergoid mix Symptomatic
Cost Perc. Cost Perc. Cost Perc.
Visits (e.g. Dermatologist) € 267 15.0% € 299 22.9% € 227 62.4%
Injection/control € 4 0.2% € 69 5.2% € 0 0.0%
Diagnostics € 21 1.2% € 21 1.6% € 0 0.0%
Treatment costs € 1,381 77.7% € 809 61.8% € 0 0.0%
Other drugs costs € 82 4.6% € 86 6.6% € 102 28.1%
Asthma € 23 1.3% € 25 1.9% € 34 9.5%
Total € 1,778 100% € 1,308 100% € 363 100.0%
Discounted and undiscounted total costs per treatment and incremental costs after a time horizon of 9 years
Discounted Undiscounted
Total Inc. vs. 5-grass tablet Total Inc. vs. 5-grass tablet
5-grass tablet € 1,707 € 1,778
Allergoid mix € 1,249 € 458 € 1,308 € 470
Symptomatic tx € 322 € 1,385 € 363 € 1,415
Discounted and undiscounted incremental costs and ICERs after a time horizon of 9 years
Inc. Costs Inc. QALYs ICER
Discounted
5-grass tablet vs. Allergoid mix € 458 0.036 € 12,593
5-grass tablet vs. Symptomatic tx € 1,385 0.081 € 17,007
Undiscounted
5-grass tablet vs. Allergoid mix € 470 0.041 € 11,576
5-grass tablet vs. Symptomatic tx € 1,415 0.090 € 15,635
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Figure 3 Scatter plot presenting the incremental costs and incremental QALYs generated in the conducted multivariate sensitivity
analyses for the 5-grass tablet vs. allergoid mix.
Figure 4 Cost effectiveness acceptability curves, showing the probability of the 5-grass tablet and allergoid mix being most cost-
effective at a range of willingness to pay thresholds.
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Table 5 Results of the scenario analyses
Scenario ΔQALY ΔCosts ICER
Base case values
- 5-grass tablet vs. allergoid mix 0.036 € 458 € 12,593
- 5-grass tablet vs. symptomatic tx 0.081 € 1,385 € 17,007
Scenario analysis 1: 100% Lump sums
- 5-grass tablet vs. allergoid mix 0.036 € 546 € 15,025
- 5-grass tablet vs. symptomatic tx 0.081 € 1,362 € 16,723
Scenario analysis 2: 100% Public to private (ambulatory)
- 5-grass tablet vs. allergoid mix 0.036 € 305 € 8,400
- 5-grass tablet vs. symptomatic tx 0.081 € 1,414 € 17,367
Scenario analysis 3: Societal perspective
- 5-grass tablet vs. allergoid mix 0.036 € 339 € 9,327
- 5-grass tablet vs. symptomatic tx 0.081 € 784 € 9,634
Scenario analysis 4: Changing utilities
- 5-grass tablet vs. allergoid mix 0.026 € 458 € 17,531
- 5-grass tablet vs. symptomatic tx 0.131 € 1,385 € 10,557
Scenario analysis 5: Shorter pollen season
- 5-grass tablet vs. allergoid mix 0.024 € 266 € 10,966
- 5-grass tablet vs. symptomatic tx 0.055 € 1,198 € 21,918
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for QoL (scenario 4). Differences in QALY gain between
the 5-grass tablet and the allergoid mix are due to differ-
ences in discontinuation rates. Decreasing the length of the
pollen season in scenario 5 affected both incremental costs
and effects. Incremental costs decreased as the 5-grass
tablet was administered for a shorter duration. Incremental
QALYs decreased as the benefits of the higher RSUI for the
5-grass tablet was applied for a shorter duration.
Discussion
The primary objective of the present analysis was to esti-
mate the costs and effects of the 5-grass tablet in compari-
son to an average mix of allergoid compounds in patients
with seasonal grass pollen-induced AR. The importance for
a cost-effective treatment of AR results from the increasing
prevalence of AR in conjunction with a lower QoL and
reduced absenteeism and/or presenteeism at work. In that
respect, the base case model outcomes can be considered
conservative as productivity losses were not included. Time
away from work due to AR was measured in a clinical trial
[39] and used for productivity losses in a scenario analysis.
Including these time losses result in higher productivity
costs for SCIT allergoid comparators.
The base case analyses revealed that point estimates for
cost-effectiveness are considered to be commonly acceptable
in Western countries. However, uncertainty surrounding the
model predictions exists. Results were especially sensitive to
changes in discontinuation rates and efficacy estimates overthe season, which was shown by univariate sensitivity ana-
lyses. This is due to the fact that AIT is the main cost com-
ponent and symptom severity is directly linked to QoL.
Furthermore, since the cost of the 5-grass tablet is
dependent on a season’s duration, incremental outcomes
were sensitive to the length of the pollen season as well.
Optimally, a direct evaluation of several treatment options
in a clinical trial is used to examine relative efficacy data. Due
to the lack of direct comparative data analyzing AIT, an indir-
ect comparison was used to compare the efficacy of relevant
treatment options in one pharmacoeconomic evaluation. In
the indirect comparison symptomatic treatment was used as
the common comparator. A fixed effects model was used ap-
plying inverse variance weighting to correct for study sample
size. Studies with a small patient population and high un-
certainty around the means attained a lower weight and
therefore had less impact on the pooled value. In addition,
inclusion criteria for the studies were very similar. Although
the chosen methodology has limitations, the determination
of comparative efficacy is more accurate by combining
published evidence of multiple trials in one meta-analytical
framework than using data from individual trials alone.
One of the most important model assumptions relates to
the extrapolation of the treatment effect. Drug treatment
was administered for three years and the effect observed
during treatment was extrapolated until the end of the
ninth year. Observations from a number of studies serve as
the basis for this assumption, showing sustained efficacy
after three years of treatment [51]. In addition, the long-
term effects of the 5-grass tablet are currently investigated
in a five-year clinical trial. Sustained efficacy of the pre- and
co-seasonal 5-grass tablet therapy have lately been demon-
strated in the post-treatment year (fourth year) [52], while
this evidence has not been demonstrated for allergoids.
Nevertheless, a conservative approach was taken in that the
on-treatment symptom score for allergoids was also as-
sumed to remain constant during the post-treatment phase.
Published cost-effective analyses on grass allergens usu-
ally project the results of the comparisons over a similar
time horizon of nine years [34,39,53].
Prevention of asthma and new sensitizations in patients
with AR are further crucial objectives of AIT. Selected aller-
gen extracts have shown a persistent long-term effect on
clinical symptoms after termination of treatment and long-
term, preventive effect on later development of asthma in
children with seasonal rhinoconjunctivitis [54]. The risk
ratio of developing asthma with AIT treatment partially
grounds on a study with SCIT and another SLIT compound
[29,30]. The latter has not shown extensive evidence of
testing dosing schemes to achieve optimal effects as the
investigated 5-grass tablet may be underdosed and might
not show optimal results.
This analysis excludes the rare occurrence of hospitaliza-
tions and the examination of consequences of potential side
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with SLIT tablets (i.e. 5-grass tablet) are, in most cases,
mild and reversible, appearing mostly only during the early
phase of treatment [14]. Although SCIT is associated with
such mild adverse events as well, severe systemic reactions,
potentially resulting in an anaphylactic shock have been ob-
served [55]. However, including these rare systemic adverse
events would not influence QoL or healthcare costs in a
significant manner on a population level.
Comparable health economic comparisons are rare in the
literature. An economic evaluation assessed the outcomes
and costs as well as cost-effectiveness of the 5-grass tablet
vs. Grazax® and Alk Depot SQ (ALK-Abello, Hørsholm,
Denmark) alongside symptomatic medication and symp-
tomatic treatment alone for grass pollen allergic rhinocon-
junctivitis [15]. In this analysis the 5-grass tablet proved to
be cost-effective compared to Grazax® and Alk Depot SQ,
and a symptomatic treatment. The cost-utility ratio of the
5-grass tablet vs symptomatic treatment was €14,728 per
QALY; incremental costs were €1,356 and incremental
QALYs 0.092. The 5 grass-tablet was the dominant strategy
compared to Grazax® and Alk Depot SQ. Four further publi-
cations of which three health economic studies assessed
Grazax and one Alk Depot SQ vs placebo, and concluded
that Alk Depot SQ was dominant versus placebo, and
Grazax® had reasonable cost-utility ratios (e.g., € 18,263 in
Germany for an annual tablet price of € 1,500) [39,53,56,57].
Conclusions
The present analysis suggests the 5-grass tablet to be cost-
effective in comparison to a selected allergoid mix, mirror-
ing a representative average of a therapeutic class in AIT.
The robustness of this statement has been addressed and
confirmed in extensive deterministic and probabilistic sen-
sitivity and scenario analyses.
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